We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

133 hedge funds and large institutions have $477M invested in Provention Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 17 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more call options, than puts

Call options by funds: $19.4M | Put options by funds: $4.53M

235% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 17

155% more capital invested

Capital invested by funds: $187M → $477M (+$290M)

124% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 17

19% more funds holding

Funds holding: 112 → 133 (+21)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
133
Holders Change
+21
Holders Change %
+18.75%
% of All Funds
2.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
38
Increased
57
Reduced
17
Closed
17
Calls
$19.4M
Puts
$4.53M
Net Calls
+$14.9M
Net Calls Change
+$11.7M

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$8.38M
2
6CM
683 Capital Management
New York
+$4.44M
3
BlackRock
BlackRock
New York
+$4.43M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$4.35M
5
Invesco
Invesco
Georgia
+$4.1M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$26.2M
2
DCM
DG Capital Management
New York
-$2.25M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.54M
4
CS
Candriam SCA
Luxembourg
-$889K
5
Osaic Holdings
Osaic Holdings
Arizona
-$691K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
1
Sessa Capital
New York
$157M – – –
BlackRock
2
BlackRock
New York
$59M +$4.43M +549,256 +11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$43.8M +$4.35M +538,679 +15%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$26.6M -$26.2M -3,250,743 -56%
State Street
5
State Street
Massachusetts
$16.5M +$2.13M +263,813 +20%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$14M +$1.01M +125,392 +10%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$12.1M +$8.38M +1,038,757 +994%
VA
8
VR Adviser
New York
$11.8M – – –
MB
9
MPM BioImpact
Massachusetts
$9.5M +$1.28M +158,139 +21%
Verition Fund Management
10
Verition Fund Management
Connecticut
$8.87M -$230K -28,449 -3%
Northern Trust
11
Northern Trust
Illinois
$6.58M +$462K +57,292 +10%
Two Sigma Investments
12
Two Sigma Investments
New York
$6.25M +$3.48M +431,108 +270%
6CM
13
683 Capital Management
New York
$5.81M +$4.44M +550,000 New
Invesco
14
Invesco
Georgia
$5.65M +$4.1M +508,393 +1,920%
Millennium Management
15
Millennium Management
New York
$4.47M +$3.42M +423,295 New
N
16
Nuveen
North Carolina
$4.35M +$237K +29,409 +8%
GTC
17
Ghost Tree Capital
New York
$4.23M +$3.23M +400,000 New
PAI
18
Palo Alto Investors
California
$4.13M – – –
Morgan Stanley
19
Morgan Stanley
New York
$4.11M +$25.8K +3,194 +0.8%
LOAMS
20
Lombard Odier Asset Management (Switzerland)
Switzerland
$3.41M +$2.61M +322,895 New
Voloridge Investment Management
21
Voloridge Investment Management
Florida
$3.28M +$2.51M +310,693 New
SSA
22
Schonfeld Strategic Advisors
New York
$3.24M +$2.47M +306,546 New
AR
23
Advisory Research
Illinois
$3.05M +$433K +53,707 +23%
EI
24
EAM Investors
California
$2.92M +$2.23M +276,250 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$2.8M +$412K +51,102 +24%
1
2 3 4 5

PRVB Hedge Fund Activity: Q4 2022 in Review

133 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2022, worth a combined $477M — up 155% from $187M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new PRVB positions and 17 closed out — a net gain of 21 holders — while 57 added to existing stakes and 17 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $8.38M. The largest seller was Adage Capital Partners, cutting an estimated $26.2M.

  • 133 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2022, up from 112 in Q3 2022.
  • Funds reported $477M of Provention Bio, Inc. Common Stock stock for Q4 2022, up 155% quarter-over-quarter.
  • 38 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2022 and 17 closed out, a net change of +21 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q4 2022 was D.E. Shaw & Co, an estimated $8.38M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q4 2022 was Adage Capital Partners, an estimated $26.2M sold.

Based on aggregated 13F filings for Q4 2022.